BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35180323)

  • 21. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P;
    Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
    Bao Y; Zhao J; Li ZZ
    Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
    Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
    Cooper TM; Sison EAR; Baker SD; Li L; Ahmed A; Trippett T; Gore L; Macy ME; Narendran A; August K; Absalon MJ; Boklan J; Pollard J; Magoon D; Brown PA
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28409853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
    Im A; Quann K; Agha M; Raptis A; Redner RL; Hou JZ; Farah R; Dorritie KA; Sehgal AR; Normolle D; Bovbjerg DH; Aggarwal N; Herman J; Lontos K; Boyiadzis M
    Am J Hematol; 2024 Mar; 99(3):380-386. PubMed ID: 38258329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
    Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
    Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
    Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
    Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Martínez-Cuadrón D; Boluda B; Martínez P; Bergua J; Rodríguez-Veiga R; Esteve J; Vives S; Serrano J; Vidriales B; Salamero O; Cordón L; Sempere A; Jiménez-Ubieto A; Prieto-Delgado J; Díaz-Beyá M; Garrido A; Benavente C; Pérez-Simón JA; Moscardó F; Sanz MA; Montesinos P;
    Ann Hematol; 2018 May; 97(5):763-772. PubMed ID: 29392425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
    DiNardo CD; Lachowiez CA; Takahashi K; Loghavi S; Kadia T; Daver N; Xiao L; Adeoti M; Short NJ; Sasaki K; Wang SA; Borthakur G; Issa G; Maiti A; Alvarado Y; Pemmaraju N; Bravo GM; Masarova L; Yilmaz M; Jain N; Andreeff M; Garcia-Manero G; Kornblau S; Ravandi F; Jabbour E; Konopleva MY; Kantarjian HM
    Am J Hematol; 2022 Aug; 97(8):1035-1043. PubMed ID: 35583199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.
    Maiti A; DiNardo CD; Wang SA; Jorgensen J; Kadia TM; Daver NG; Short NJ; Yilmaz M; Pemmaraju N; Borthakur G; Bose P; Issa GC; Ferrajoli A; Jabbour EJ; Jain N; Garcia-Manero G; Ohanian M; Takahashi K; Montalban-Bravo G; Masarova L; Burger JA; Thompson PA; Verstovsek S; Sasaki K; Andreeff M; Rausch CR; Montalbano KS; Pierce S; Qiao W; Ning J; Kantarjian HM; Konopleva MY; Ravandi F
    Blood Adv; 2021 Apr; 5(7):1876-1883. PubMed ID: 33792630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
    Gore L; Triche TJ; Farrar JE; Wai D; Legendre C; Gooden GC; Liang WS; Carpten J; Lee D; Alvaro F; Macy ME; Arndt C; Barnette P; Cooper T; Martin L; Narendran A; Pollard J; Meshinchi S; Boklan J; Arceci RJ; Salhia B
    Clin Epigenetics; 2017; 9():108. PubMed ID: 29034009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
    Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
    Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel regimen for relapsed/refractory adult acute myeloid leukemia using a
    Mims AS; Mishra A; Orwick S; Blachly J; Klisovic RB; Garzon R; Walker AR; Devine SM; Walsh KJ; Vasu S; Whitman S; Marcucci G; Jones D; Heerema NA; Lozanski G; Caligiuri MA; Bloomfield CD; Byrd JC; Piekarz R; Grever MR; Blum W
    Haematologica; 2018 Jun; 103(6):982-987. PubMed ID: 29567781
    [No Abstract]   [Full Text] [Related]  

  • 36. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
    Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
    Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
    Walter RB; Medeiros BC; Gardner KM; Orlowski KF; Gallegos L; Scott BL; Hendrie PC; Estey EH
    Haematologica; 2014 Jan; 99(1):54-9. PubMed ID: 24142996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Saygin C; Larkin K; Blachly JS; Orwick S; Ngankeu A; Gregory CT; Phelps MA; Mani S; Walker A; Garzon R; Vasu S; Walsh KJ; Bhatnagar B; Klisovic RB; Grever MR; Marcucci G; Byrd JC; Blum W; Mims AS
    Am J Hematol; 2020 Dec; 95(12):1457-1465. PubMed ID: 32777116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.